Engineered insulin-like growth factor-1 for improved smooth muscle regeneration

Biomaterials

Volumn 33, Issue 2, 2012, Pages 494-503

  Lorentz, Kristen M ^a   Yang, Lirong ^a   Frey, Peter ^a,b   Hubbell, Jeffrey A ^a  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bladder tissue engineering; Fibrin; Growth factors; In vivo test; Recombinant protein; Smooth muscle cell

Indexed keywords

BLADDER TISSUE ENGINEERING; FIBRIN; GROWTH FACTORS; IN VIVO TEST; RECOMBINANT PROTEIN; SMOOTH MUSCLE CELL;

BIOACTIVITY; CELL PROLIFERATION; CELLS; INSULIN; PEPTIDES; PHOSPHORYLATION; TISSUE ENGINEERING;

MUSCLE;

ALPHA 2 ANTIPLASMIN; ALPHA 2 ANTIPLASMIN SOMATOMEDIN C FUSION PROTEIN; BLOOD CLOTTING FACTOR 13A; FIBRIN; HYBRID PROTEIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER INJURY; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MUSCLE REGENERATION; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; RAT; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; TISSUE ENGINEERING; URINARY TRACT; WILD TYPE;

ALPHA-2-ANTIPLASMIN; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; EXPRESSED SEQUENCE TAGS; FEMALE; FIBRIN; GENETIC ENGINEERING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SMOOTH; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; REGENERATION; URINARY BLADDER;

RATTUS;

EID: 80055104248     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.088     Document Type: Article

References (47)

1. Friedrich N., Alte D., Volzke H., Spilcke-Liss E., Ludemann J., Lerch M.M., et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the study of health in Pomerania (SHIP). Growth Horm IGF Res 2008, 18:228-237.
2. Campbell P.G., Durham S.K., Hayes J.D., Suwanichkul A., Powell D.R. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 1999, 274:30215-30221.
3. Ren H., Accili D., Duan C. Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways. Proc Natl Acad Sci U S A 2010, 107:5857-5862.
4. Winn N., Paul A., Musaro A., Rosenthal N. Insulin-like growth factor isoforms in skeletal muscle aging, regeneration, and disease. Cold Spring Harb Symp Quant Biol 2002, 67:507-518.
5. Ruvinov E., Leor J., Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011, 32:565-578.
6. Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005, 168:193-199.
7. Rabinovsky E.D. The multifunctional role of IGF-1 in peripheral nerve regeneration. Neurol Res 2004, 26:204-210.
8. Capito R.M., Spector M. Collagen scaffolds for nonviral IGF-1 gene delivery in articular cartilage tissue engineering. Gene Ther 2007, 14:721-732.
9. Srouji S., Blumenfeld I., Rachmiel A., Livne E. Bone defect repair in rat tibia by TGF-beta1 and IGF-1 released from hydrogel scaffold. Cell Tissue Bank 2004, 5:223-230.
10. Jia G., Mitra A.K., Gangahar D.M., Agrawal D.K. Insulin-like growth factor-1 induces phosphorylation of PI3K-Akt/PKB to potentiate proliferation of smooth muscle cells in human saphenous vein. Exp Mol Pathol 2010, 89:20-26.
11. Allen T.R., Krueger K.D., Hunter W.J., Agrawal D.K. Evidence that insulin-like growth factor-1 requires protein kinase C-epsilon, PI3-kinase and mitogen-activated protein kinase pathways to protect human vascular smooth muscle cells from apoptosis. Immunol Cell Biol 2005, 83:651-667.
12. Korossis S., Bolland F., Ingham E., Fisher J., Kearney J., Southgate J. Review: tissue engineering of the urinary bladder: considering structure-function relationships and the role of mechanotransduction. Tissue Eng 2006, 12:635-644.
13. Stampfer D.S., McDougal W.S., McGovern F.J. The use of in bowel urology. Metabolic and nutritional complications. Urol Clin North Am 1997, 24:715-722.
14. Somani B.K., Kumar V., Wong S., Pickard R., Ramsay C., Nabi G., et al. Bowel dysfunction after transposition of intestinal segments into the urinary tract: 8-year prospective cohort study. J Urol 2007, 177:1793-1798.
15. Atala A. Tissue engineering of human bladder. Br Med Bull 2011, 97:81-104.
16. Schense J.C., Hubbell J.A. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem 1999, 10:75-81.
17. Adelow C., Segura T., Hubbell J.A., Frey P. The effect of enzymatically degradable poly(ethylene glycol) hydrogels on smooth muscle cell phenotype. Biomaterials 2008, 29:314-326.
18. Southgate J., Hutton K.A., Thomas D.F., Trejdosiewicz L.K. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994, 71:583-594.
19. Lorentz K.M., Kontos S., Frey P., Hubbell J.A. Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials 2011, 32:430-438.
20. Campbell P.G., Novak J.F., Yanosick T.B., McMaster J.H. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 1992, 130:1401-1412.
21. Lykidis D., Van Noorden S., Armstrong A., Spencer-Dene B., Li J., Zhuang Z., et al. Novel zinc-based fixative for high quality DNA, RNA and protein analysis. Nucleic Acids Res 2007, 35:e85.
22. Liu X., Lin C.S., Spencer E.M., Lue T.F. Insulin-like growth factor-I promotes proliferation and migration of cavernous smooth muscle cells. Biochem Biophys Res Commun 2001, 280:1307-1315.
23. Kim S.O., Lee Y.I. High-level expression and simple purification of recombinant human insulin-like growth factor I. J Biotechnol 1996, 48:97-105.
24. Perrault R., Wright B., Storie B., Hatherell A., Zahradka P. Tyrosine kinase-independent activation of extracellular-regulated kinase (ERK) 1/2 by the insulin-like growth factor-1 receptor. Cell Signal 2011, 23:739-746.
25. Rolfe K.J., Cambrey A.D., Richardson J., Irvine L.M., Grobbelaar A.O., Linge C. Dermal fibroblasts derived from fetal and postnatal humans exhibit distinct responses to insulin like growth factors. BMC Dev Biol 2007, 7:124.
26. Johansson G.S., Arnqvist H.J. Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 2006, 291:E1124-E1130.
27. Stratton M.S., Yang X., Sreejayan N., Ren J. Impact of insulin-like growth factor-I on migration, proliferation and Akt-ERK signaling in early and late-passages of vascular smooth muscle cells. Cardiovasc Toxicol 2007, 7:273-281.
28. Messing E.M., Reznikoff C.A. Normal and malignant human urothelium: in vitro effects of epidermal growth factor. Cancer Res 1987, 47:2230-2235.
29. Metalli D., Lovat F., Tripodi F., Genua M., Xu S.Q., Spinelli M., et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010, 176:2997-3006.
30. de Boer W.I., Schuller A.G., Vermey M., van der Kwast T.H. Expression of growth factors and receptors during specific phases in regenerating urothelium after acute injury in vivo. Am J Pathol 1994, 145:1199-1207.
31. Ehrbar M., Metters A., Zammaretti P., Hubbell J.A., Zisch A.H. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J Control Release 2005, 101:93-109.
32. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF-fibrin matrices for endothelialization. J Control Release 2001, 72:101-113.
33. Andreadis S.T., Hamoen K.E., Yarmush M.L., Morgan J.R. Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system. Faseb J 2001, 15:898-906.
34. Hinz B., Gabbiani G. Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives. F1000 Biol Rep 2010, 2:78.
35. Ahmann K.A., Weinbaum J.S., Johnson S.L., Tranquillo R.T. Fibrin degradation enhances vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue constructs fabricated in vitro. Tissue Eng Part A 2010, 16:3261-3270.
36. Brown B.N., Valentin J.E., Stewart-Akers A.M., McCabe G.P., Badylak S.F. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 2009, 30:1482-1491.
37. Davis M.E., Hsieh P.C., Takahashi T., Song Q., Zhang S., Kamm R.D., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006, 103:8155-8160.
38. Beckert S., Hierlemann H., Muschenborn N., Witte M., Ranke M., Coerper S. Experimental ischemic wounds: correlation of cell proliferation and insulin-like growth factor I expression and its modification by different local IGF-I release systems. Wound Repair Regen 2005, 13:278-283.
39. Spies M., Nesic O., Barrow R.E., Perez-Polo J.R., Herndon D.N. Liposomal IGF-1 gene transfer modulates pro- and anti-inflammatory cytokine mRNA expression in the burn wound. Gene Ther 2001, 8:1409-1415.
40. Wildemann B., Bamdad P., Holmer C., Haas N.P., Raschke M., Schmidmaier G. Local delivery of growth factors from coated titanium plates increases osteotomy healing in rats. Bone 2004, 34:862-868.
41. Takahashi T., Ishida K., Itoh K., Konishi Y., Yagyu K.I., Tominaga A., et al. IGF-I gene transfer by electroporation promotes regeneration in a muscle injury model. Gene Ther 2003, 10:612-620.
42. Musaro A., McCullagh K., Paul A., Houghton L., Dobrowolny G., Molinaro M., et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001, 27:195-200.
43. Howell T.H., Fiorellini J.P., Paquette D.W., Offenbacher S., Giannobile W.V., Lynch S.E. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J Periodontol 1997, 68:1186-1193.
44. Chikamoto N., Chikama T., Yamada N., Nishida T., Ishimitsu T., Kamiya A. Efficacy of substance P and insulin-like growth factor-1 peptides for preventing postsurgical superficial punctate keratopathy in diabetic patients. Jpn J Ophthalmol 2009, 53:464-469.
45. Nakagawa T., Sakamoto T., Hiraumi H., Kikkawa Y.S., Yamamoto N., Hamaguchi K., et al. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. BMC Med 2010, 8:76.
46. Upton Z., Cuttle L., Noble A., Kempf M., Topping G., Malda J., et al. Vitronectin: growth factor complexes hold potential as a wound therapy approach. J Invest Dermatol 2008, 128:1535-1544.
47. Van Lonkhuyzen D.R., Hollier B.G., Shooter G.K., Leavesley D.I., Upton Z. Chimeric vitronectin:insulin-like growth factor proteins enhance cell growth and migration through co-activation of receptors. Growth Factor 2007, 25:295-308.